Folgen
Adrián LLerena MD PhD Professor Clinical Pharmacology
Adrián LLerena MD PhD Professor Clinical Pharmacology
INUBE Biosanitary University Research Institute. University of Extremadura. CICAB Clinical Research
Bestätigte E-Mail-Adresse bei unex.es - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake …
JK Hicks, JR Bishop, K Sangkuhl, DJ Müller, Y Ji, SG Leckband, ...
Clinical Pharmacology & Therapeutics 98 (2), 127-134, 2015
10412015
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
L Bertilsson, JA Carrillo, ML Dahl, A Llerena, C Alm, U Bondesson, ...
British journal of clinical pharmacology 38 (5), 471-473, 1994
3931994
Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype
Ü Yasar, C Forslund‐Bergengren, G Tybring, P Dorado, A LLerena, ...
Clinical Pharmacology & Therapeutics 71 (1), 89-98, 2002
2912002
An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels
J De Leon, G Schoretsanitis, RL Smith, E Molden, A Solismaa, N Seppälä, ...
Pharmacopsychiatry 55 (02), 73-86, 2022
2172022
Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations
A LLerena, MEG Naranjo, F Rodrigues-Soares, EM Penas-LLedó, ...
Expert opinion on drug metabolism & toxicology 10 (11), 1569-1583, 2014
2022014
Relationship between personality and debrisoquine hydroxylation capacity: suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6
A Llerena, G Edman, J Cobaleda, J Benitez, D Schalling, L Bertilsson
Acta Psychiatrica Scandinavica 87 (1), 23-28, 1993
1961993
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
A LLerena, C Alm, ML Dahl, B Ekqvist, L Bertilsson
Therapeutic drug monitoring 14 (2), 92-97, 1992
1841992
Pharmacogenomic information in drug labels: European Medicines Agency perspective
F Ehmann, L Caneva, K Prasad, M Paulmichl, M Maliepaard, A Llerena, ...
The pharmacogenomics journal 15 (3), 201-210, 2015
1782015
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update
JH Karnes, AE Rettie, AA Somogyi, R Huddart, AE Fohner, CM Formea, ...
Clinical Pharmacology & Therapeutics 109 (2), 302-309, 2021
1592021
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education
D Gurwitz, JE Lunshof, G Dedoussis, CS Flordellis, U Fuhr, J Kirchheiner, ...
The pharmacogenomics journal 5 (4), 221-225, 2005
1492005
Assessing clinical and functional outcomes in a gene–environment interaction study in first episode of psychosis (PEPs)
M Bernardo, M Bioque, M Parellada, JS Ruiz, MJ Cuesta, A Llerena, ...
Revista de Psiquiatría y Salud Mental (English Edition) 6 (1), 4-16, 2013
1372013
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
P Dorado, R Berecz, MJ Norberto, Ü Yasar, ML Dahl, A LLerena
European journal of clinical pharmacology 59, 221-225, 2003
1332003
Disposition of clozapine in man: lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms.
ML Dahl, A Llerena, U Bondesson, L Lindstrom, L Bertilsson
British journal of clinical pharmacology 37 (1), 71-74, 1994
1281994
Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers
A LLerena, ML Dahl, B Ekqvist, L Bertilsson
Therapeutic drug monitoring 14 (3), 261-264, 1992
1171992
Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
A Llerena, J Cobaleda, C Martinez, J Benitez
European journal of drug metabolism and pharmacokinetics 21, 129-138, 1996
1161996
QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations
A Llerena, R Berecz, P Dorado, A De la Rubia
Journal of psychopharmacology 18 (2), 189-193, 2004
1112004
Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
A LLerena, P Dorado, R Berecz, AP González, EM Peñas-LLedó
European journal of clinical pharmacology 59, 869-873, 2004
1052004
Carbamazepine adverse drug reactions
I Fricke-Galindo, A LLerena, H Jung-Cook, M López-López
Expert review of clinical pharmacology 11 (7), 705-718, 2018
1002018
Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use
P Dorado, MC Cáceres, E Pozo-Guisado, ML Wong, J Licinio, A LLerena
Biotechniques 39 (10 Suppl), S571-S754, 2005
1002005
CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
A Llerena, P Dorado, R Ramírez, I González, M Alvarez, EM Peñas-Lledó, ...
The pharmacogenomics journal 12 (2), 176-183, 2012
982012
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20